全文获取类型
收费全文 | 5538篇 |
免费 | 306篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 138篇 |
妇产科学 | 162篇 |
基础医学 | 702篇 |
口腔科学 | 146篇 |
临床医学 | 375篇 |
内科学 | 1439篇 |
皮肤病学 | 110篇 |
神经病学 | 514篇 |
特种医学 | 142篇 |
外科学 | 919篇 |
综合类 | 31篇 |
预防医学 | 321篇 |
眼科学 | 82篇 |
药学 | 235篇 |
中国医学 | 15篇 |
肿瘤学 | 476篇 |
出版年
2023年 | 53篇 |
2022年 | 114篇 |
2021年 | 285篇 |
2020年 | 120篇 |
2019年 | 217篇 |
2018年 | 229篇 |
2017年 | 165篇 |
2016年 | 138篇 |
2015年 | 143篇 |
2014年 | 226篇 |
2013年 | 291篇 |
2012年 | 460篇 |
2011年 | 521篇 |
2010年 | 262篇 |
2009年 | 239篇 |
2008年 | 357篇 |
2007年 | 361篇 |
2006年 | 345篇 |
2005年 | 327篇 |
2004年 | 256篇 |
2003年 | 239篇 |
2002年 | 208篇 |
2001年 | 28篇 |
2000年 | 28篇 |
1999年 | 40篇 |
1998年 | 42篇 |
1997年 | 28篇 |
1996年 | 15篇 |
1995年 | 20篇 |
1994年 | 14篇 |
1993年 | 18篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 9篇 |
1980年 | 3篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1947年 | 1篇 |
1944年 | 1篇 |
1942年 | 1篇 |
1936年 | 1篇 |
1920年 | 1篇 |
排序方式: 共有5878条查询结果,搜索用时 15 毫秒
91.
92.
Lorena Álvarez-Rodríguez Marcos López-Hoyos Eugenio Carrasco-Marín Cristina Mata Jaime Calvo-Alén Elena Aurrecoechea Ricardo Blanco Teresa Ruiz Pedro Muñoz Cacho Ignacio Villa Víctor Manuel Martínez-Taboada 《Reumatología clinica》2012,8(6):321-327
ObjectiveTo investigate whether there is association between the rs20541 (R130Q) polymorphism in the IL-13 gene with disease susceptibility and clinical subsets in patients with elderly-associated inflammatory chronic diseases.Material and methods78 patients with giant cell arteritis (GCA), 174 with polymyalgia rheumatica (PMR), 90 elderly-onset rheumatoid arthritis (EORA), and 465 healthy controls from the same geographic area were studied. The rs20541 (R130Q) polymorphism in the IL-13 gene was evaluated by PCR-RFLP. Circulating levels of IL-13 were measured by ELISA.ResultsA higher frequency of the AA genotype [2.349 (0.994-5.554)], as well as the allele A [1.589 (1.085-2.328] and the A carriers [1.656 (1.021-2.686)] (p < 0.05) was observed in the GCA patients. No significant differences were observed in the PMR and EORA patients as compared with the healthy controls. Neither difference was observed among the different disease groups studied. In GCA patients, differences in the genotype were associated with a worse prognosis. In PMR patients, the AA genotype was associated with higher levels of serum IL-13 than the GA one. However, such an association was not detected for controls and the other disease groups.ConclusionsGCA is more frequent in carriers of the rs20541 (R130Q) polymorphism in the IL-13 gene. The utility of this polymorphism to predict the GCA prognosis must be confirmed in studies with a higher number of patients. 相似文献
93.
94.
95.
Fabián Matías Caro María Laura Alberti Federico Campins Juan Ignacio Enghelmayer Martín Eduardo Fernández Diana Lancellotti Tulio Papucci Javier Adrián Sebastiani Francisco Paulin 《Archivos de bronconeumologia》2019,55(2):75-80
Introduction
Pirfenidone was the first antifibrotic drug approved in Argentina for idiopathic pulmonary fibrosis (IPF). Outcomes in real life may differ from the results of clinical trials. The primary endpoint was to study the tolerance of pirfenidone in real life. Secondary endpoints were to analyze effectiveness and reasons for discontinuation.Materials and methods
Retrospective observational study conducted in four specialized centers in Argentina. We analyzed the medical records of patients with IPF who received pirfenidone between June 2013 and September 2016. Adverse events (AE) and the variables that could influence these results were analyzed. Forced vital capacity (FVC%) parameters were also compared between the pre-pirfenidone and post-pirfenidone periods.Results
Fifty patients were included, 38 (76%) men, with mean age (SD) 67.8 (8.36) years. Mean (SD) exposure to pirfenidone was 645.68 (428.19) days, with a mean daily dose (SD) of 2064.56 mg (301.49). Nineteen AEs in 15 patients (30%) were reported: nausea (14%), asthenia (10%) and skin rash (8%). A total of 18 patients (36%) interrupted treatment, only 1 definitively. The most frequent reason for discontinuation was failure of suppliers to provide the drug (9 subjects; 18%). We compared the evolution of FVC% between the pre-pirfenidone and post-pirfenidone periods, and found a mean (SD) FVC% decline of 4.03% (7.63) pre-pirfenidone and 2.64% (7.1) post-pirfenidone (P=.534).Conclusions
In our study, pirfenidone was well tolerated and associated with a reduction in FVC decline, although without reaching statistical significance. 相似文献96.
Sarah Heili Frades María del Pilar Carballosa de Miguel Alba Naya Prieto Marina Galdeano Lozano Xavier Mate García Ignacio Mahillo Fernández Itziar Fernández Ormaechea Laura Álvarez Suárez Farah Ezzine de Blas María José Checa Venegas Nicolás González Mangado Germán Peces Barba 《Archivos de bronconeumologia》2019,55(12):634-641
IntroductionHistorically, it has been assumed that Intermediate Respiratory Care Units (IRCU) were efficient, because they saved costs by reducing the number of admissions to intensive care units (ICU), and effective, because they specialized in respiratory diseases.MethodsThe number of IRCU admissions and mortality rate, historically and in 2016, were evaluated. For 2016, the grouped Related Diagnostic Groups (DRGs) were also described, and the savings achieved under all budgetary headings by avoiding UCI stays were calculated. A multivariate analysis was performed to associate costs with mean weights and complexity, and multiple logistic regression was performed on all patients admitted from 2004 to 2017 to describe the variables associated with mortality in our unit.ResultsAn IRCU generates savings of €500,000/year by reducing length of ICU stay. Analysis of the 2016 cohort shows that costs correlate with mean weight and mortality, and consequently complexity. The multivariate logistic regression analysis of the 2004–2017 cohort found respiratory frequency, leukopenia, anemia, hyperkalemia, and acidosis to be the variables best associated with mortality. The area under the curve for the logistic model was 0.75.ConclusionThe IRCU analyzed in our study was efficient in terms of ‘avoided costs’ and savings associated with complexity. Our results suggest that IRCUs have a lower mortality rate than other similar units, and are therefore a safe environment for patients. 相似文献
97.
98.
99.
100.
Escarlata Angullo-Martínez Enrique Carretero-Anibarro Ignacio Manuel Snchez Barrancos Xavier Cos Claramunt Domingo Orozco Beltrn Jos Luis Torres Baile Patxi Ezkurra Loiola en representacin del Grupo de Trabajo de Diabetes de la SemFyC en representacin del Grupo de Trabajo de Diabetes de la SemFyC 《Atencion primaria / Sociedad Espa?ola de Medicina de Familia y Comunitaria》2021,53(4)
Las circunstancias actuales provocadas por la COVID-19 nos obligan a los profesionales de atención primaria a idear nuevas formas de garantizar la atención sanitaria de nuestros pacientes con diabetes tipo 2 (DM2). Existen evidencias que respaldan la eficacia de la telemedicina en el control glucémico de los pacientes con DM2. Ante la rápida adaptación de la práctica clínica al uso de la telemedicina, el Grupo de Trabajo de Diabetes de la Sociedad Española de Medicina Familiar y Comunitaria (SemFyC) optó por elaborar un documento de consenso plasmado en un algoritmo de actuación/seguimiento telemático en la atención de los pacientes con DM2.Palabras clave: Telemedicina, Diabetes mellitus tipo 2, COVID-19 相似文献